Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Medpace Holdings, Inc. recently reported its second-quarter 2025 earnings, revealing both strengths and challenges.</li><li>Revenue for the quarter was $603.3 million, marking a 14.2% increase year-over-year.</li><li>The uptick was driven by higher reimbursable activities, particularly in therapeutic areas like metabolic studies where costs are higher than average, alongside a shift in therapeutic focus away from oncology.</li></ul>

Medpace Holdings, Inc. recently reported its second-quarter 2025 earnings, revealing both strengths and challenges.Revenue for the quarter was $603.3 million, marking a 14.2% increase year-over-year.The uptick was driven by higher reimbursable activities, particularly in therapeutic areas like metabolic studies where costs are higher than average, alongside a shift in therapeutic focus away from oncology.

Medpace Is Expanding Decentralized Clinical Trials & Improving Global Trial Capabilities But Is It ENOUGH?

<ul><li>Medpace Holdings, Inc. recently announced its financial results for the first quarter of 2025, revealing a nuanced performance amid a challenging industry landscape.</li><li>Regarding revenue, Medpace achieved $558.6 million, marking a year-over-year increase of 9.3%.</li><li>This growth was somewhat driven by an increase in reimbursable costs, which constituted a significant part of the revenue.</li></ul>

Medpace Holdings, Inc. recently announced its financial results for the first quarter of 2025, revealing a nuanced performance amid a challenging industry landscape.Regarding revenue, Medpace achieved $558.6 million, marking a year-over-year increase of 9.3%.This growth was somewhat driven by an increase in reimbursable costs, which constituted a significant part of the revenue.

Medpace Holdings: Interesting Backlog Growth & Book-to-Bill Ratios But Is It Enough?

<ul><li>Medpace Holdings, Inc. reported for the fourth quarter and full fiscal year 2024, showcasing a mixed financial environment defined by growth challenges yet significant earnings improvements.</li><li>For the year, Medpace recorded revenues of $2.11 billion, marking an 11.8% increase from the previous year, with fourth-quarter revenues of $536.6 million, up by 7.7% year-over-year.</li><li>These increments indicate a steady income trajectory, albeit amidst a business environment tempered by rising cancellations and decreased new business awards.</li></ul>

Medpace Holdings, Inc. reported for the fourth quarter and full fiscal year 2024, showcasing a mixed financial environment defined by growth challenges yet significant earnings improvements.For the year, Medpace recorded revenues of $2.11 billion, marking an 11.8% increase from the previous year, with fourth-quarter revenues of $536.6 million, up by 7.7% year-over-year.These increments indicate a steady income trajectory, albeit amidst a business environment tempered by rising cancellations and decreased new business awards.

Medpace: Why Biotech Firms Are Locking in Long-Term Deals With This CRO?

<ul><li>Medpace Holdings, Inc. reported its third-quarter 2024 earnings, showcasing a mixed bag of results influenced by both positive performance metrics and notable challenges.</li><li>On the earnings call, company leadership discussed these results and the ongoing dynamics impacting its business.</li><li>One of the highlights was Medpace's revenue for the third quarter, which reached $533.3 million, marking an 8.3% year-over-year increase.</li></ul>

Medpace Holdings, Inc. reported its third-quarter 2024 earnings, showcasing a mixed bag of results influenced by both positive performance metrics and notable challenges.On the earnings call, company leadership discussed these results and the ongoing dynamics impacting its business.One of the highlights was Medpace's revenue for the third quarter, which reached $533.3 million, marking an 8.3% year-over-year increase.

Medpace Holdings: Dealing With Funding Dynamics & Critical Market Challenges! - Major Drivers

<ul><li>Medpace, in their second quarter 2024 earnings call, provided a detailed overview of their financial and operational performance.</li><li>The company faced challenges in the quarter, notably with net new business awards entering backlog decreasing by 4.1% year over year to $551 million, influenced by higher cancellations.</li><li>Despite this setback in the backlog, Medpace reported a revenue increase of 14.6% year-over-year, totaling $528.1 million for the quarter.</li></ul>

Medpace, in their second quarter 2024 earnings call, provided a detailed overview of their financial and operational performance.The company faced challenges in the quarter, notably with net new business awards entering backlog decreasing by 4.1% year over year to $551 million, influenced by higher cancellations.Despite this setback in the backlog, Medpace reported a revenue increase of 14.6% year-over-year, totaling $528.1 million for the quarter.

Medpace Holdings Inc.: An Analysis Of Its Business Strategy

United States

Medpace Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides cardiovascular, hematology, oncology, neurology, pediatrics, nephrology, and diagnostic services. Medpace Holdings serves patients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Medpace Holdings Inc (MEDP US)

Medpace Is Expanding Decentralized Clinical Trials & Improving Global Trial Capabilities But Is It ENOUGH?

Medpace Holdings, Inc. recently reported its second-quarter 2025 earnings, revealing both strengths and challenges. Revenue for the quarter was...

Baptista Research

Medpace Holdings: Interesting Backlog Growth & Book-to-Bill Ratios But Is It Enough?

Medpace Holdings, Inc. recently announced its financial results for the first quarter of 2025, revealing a nuanced performance amid a challenging...

Baptista Research

Medpace: Why Biotech Firms Are Locking in Long-Term Deals With This CRO?

Medpace Holdings, Inc. reported for the fourth quarter and full fiscal year 2024, showcasing a mixed financial environment defined by growth...

Baptista Research

Medpace Holdings: Dealing With Funding Dynamics & Critical Market Challenges! - Major Drivers

Medpace Holdings, Inc. reported its third-quarter 2024 earnings, showcasing a mixed bag of results influenced by both positive performance metrics...

Baptista Research

Medpace Holdings Inc.: An Analysis Of Its Business Strategy

Medpace, in their second quarter 2024 earnings call, provided a detailed overview of their financial and operational performance. The company...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)